Careers | Contact Us

About Us


BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
BioLineRx’s pipeline currently consists of six clinical stage therapeutic candidates:

BL-1040, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients which was out-licensed to Bellerophon Therapeutics (f/k/a Ikaria), (pivotal CE Mark registration trial);

BL-8040, for acute myeloid leukemia (AML) and other hematological cancers (Phase II);

BL-7010, a novel, non-absorbable, high molecular weight polymer intended for the treatment of celiac disease (Phase I);

BL-5010, a novel formulation for non-surgical removal of skin lesions (Phase I/II clinical trial completed);

BL-7040, a novel, orally available synthetic oligonucleotide for the treatment of inflammatory bowel disease (Phase II);

BL-8020, an orally available interferon-free treatment for Hepatitis C (HCV) and other viral indications (Phase I/II).

Additional compounds are currently in the pipeline at various stages of pre-clinical development for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.